BioCentury
ARTICLE | Clinical News

TGR-1202: Phase IIb started

June 13, 2016 7:00 AM UTC

TG Therapeutics began the open-label, U.S. Phase IIb UNITY-DLBCL trial to evaluate oral TGR-1202 daily with or without IV ublituximab ( TG-1101) in about 200 patients. TG Therapeutics has exclusive, w...